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ABSTRACT 
A model system involving the formation of protein-dextran complexes has been 
investigated with a view to improving existing methods of drug administration. 
Activation of the dextran was achieved by periodate oxidation to give levels of 7%, 21 % 
and 56% activated glucose moieties. The protein-dextran complexes were investigated 
with the prospect of obtaining sustained release of proteins from the dextran in an 
unmodified form. Covalent conjugation of proteins to carbohydrate polymers is known 
to confer stability on the protein. The proteins in this study were bound to the dextran 
through imine bonds. The proteins investigated were lysozyme, trypsin, amylase, alcohol 
dehydrogenase and catalase. The selection covered a range of molecular weights and 
varying enzymatic activities. 
As might be predicted, the speed of complex formation was shown to be greater at the 
21 % level of activation compared to the 7% activation of dextran in all cases studied. 
Lysozyme, the smallest protein, readily formed complexes at all three levels of activation. 
At the 56% level the resulting complex had an extremely high MW, greater than lMDa. 
The extensive binding between the dextran and lysozyme molecules resulted in a 
complex that was inactive and showed no signs of releasing any lysozyme, active or 
inactive. At the lower levels of activation, complex was formed with relative ease. 
Upon conjugation lysozyme exhibited only minimal activity. Release of a lysozyme-like 
species with normal lytic activity was observed. 
Precautions were taken to minimise possible autolysis in the trypsin study. Once 
complexed it was postulated that autolysis would be prevented or minimised. Similarly 
the 56% level of activation appeared to be too high to obtain a viable complex for facile 
trypsin release. Sustained release of a trypsin-like protein was observed with complexes 
at the 7% and 21 % levels. SEC and SDS-PAGE, in conjunction with a positive BAPNA 
assay gave support to the released species being trypsin-like. While complexed to the 
dextran trypsin showed no signs of activity. Released trypsin-like species and unreacted 
trypsin showed similar tryptic maps from a synthetic peptide, the peptide was designed to 
show distinctive fragments. 
a-Amylase, twice the MW of trypsin and over three times the MW oflysozyme, formed 
complexes with ease at both 7% and 21 % levels of activation. Conjugation to dextran 
did not effect the activity of a-amylase. Over time the release of an a-amylase-like 
species from the complex was observed. 
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Alcohol dehydrogenase and catalase are both high MW proteins. Complex formation 
was observed for each protein. Subsequent experiments showed that upon release the 
proteins appeared to dissociate, most probably into their subunits. It is also possible that 
the dimers and monomers bound to the dextran. The main advantage of conjugation in 
this case appeared to be to confer stability on the proteins. The ADH-complex exhibited 
enzymatic activity. 
At 7% and 21 % activation levels the lower MW proteins formed complexes with dextran 
that exhibited release of a protein species. The higher MW proteins were possibly 
stabilised when conjugated to dextran, but dissociated upon release. Investigations have 
shown that the level of activation chosen affects the extent of binding and therefore the 
functions of the resultant complex. Thus activation levels can be manipulated depending 
on the desired result. While lower dextran activation levels appeared to be more suited 
for smaller MW proteins, there were indications that the larger MW proteins could form 
beneficial complexes at higher activation levels. Results indicated that conjugation to 
periodate activated dextran could be extended to further proteins with the possibility of 
therapeutic or commercial applications. 
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